UK Support to Gavi 2026–2030
My noble friend the Minister of State for International Development, Latin America and Caribbean (The Rt Hon Baroness Chapman of Darlington) has today made the following statement:
I wish to inform the House that the Government has pledged new support to Gavi, the Vaccine Alliance. This announcement was made at the Global Summit on Health and Prosperity through Immunisation in Brussels on 25 June, reaffirming this Government’s commitment to multilateral efforts on global health.
As Gavi’s inaugural Board Chair, Nelson Mandela, noted over twenty years ago “Life or death for a young child too often depends on whether he or she is born in a country where vaccines are available”. Whilst we have made remarkable progress in correcting for these inequities, the job is still not done. More than 5 million children under 5 still die each year from preventable causes including vaccine-preventable diseases.
The UK Government was proud to have supported the creation of Gavi – who since inception in 2000 have enabled the vaccination of over 1 billion children, saving an estimated 18 million lives. Today we are proud to invest alongside others in the sustained efforts to support every child to have a fairer start in life.
The UK will invest £1.25 billion over five years, from 2026 to 2030, in support of Gavi’s mission. This will support the immunisation of 62.5m children, saving around 1.25m lives.
But it is not just because this investment is pursuing an obvious good that we invest. We also make this commitment as Gavi remains a vital partner in delivering our ambition for a safer and more prosperous world.
The threats we face are evolving. Covid-19 taught us that diseases do not respect borders, and with Anti-Microbial Resistance (AMR) already contributing to rising mortality, the link between national and global health security has never been clearer. Gavi supports UK public health - and therefore protects the NHS - by preventing disease. Gavi prevents disease both through routine immunisation and through global stockpiles of vaccines to respond to outbreaks – such as Ebola or cholera – in order to prevent these diseases reaching our shores.
Gavi works directly with UK pharmaceutical companies to develop and manufacture vaccines, for example the MenFive vaccine against meningitis and the RTS,S and R21 vaccines against malaria. This investment in the UK's science sector supports economic growth and job creation, putting money in the pockets of British people.
As the UK pursues a modern approach to development, Gavi must also continue to deliver on its model of partnership, not paternalism. In the last 25 years, 19 countries have successfully transitioned from Gavi support to fully self-finance their immunisation programmes and some have themselves become Gavi donors. But there is more to be done.
Multilateral health organisations must go further to maximise impact. This means putting country needs at the heart of the future approach. It requires simplifying processes, working more closely together, and strengthening national health systems to deliver. It needs the multilateral system to help countries take the lead in delivering universal health coverage and accelerate the move to funding their own systems.